Refractory sickle cell leg ulcer: Is heparan sulphate a new hope?
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Blackwell Publishing Ltd
Abstract
Patients with sickle cell disease are known to have recurrent lower extremity ulcers that have a high pain score and are resistant to conventional means of wound therapy. This study reports the successful use of synthetic heparan sulphate (Cacipliq20®, OTR3, Paris, France) in the treatment of a sickle cell ulcer that had failed to respond to several other means of treatment. Therapeutic success was assessed by complete wound coverage and vast improvement in pain score. This is the first study to report use of heparan sulphate in sickle cell ulcers. © 2016 John Wiley & Sons Ltd and Medicalhelplines.com Inc.
Description
Keywords
Cacipliq20, Glucose amino glycans, Heparan sulphate, Sickle cell ulcer, Ulcer, Administration, topical, Adult, Anemia, sickle cell, Female, Heparitin sulfate, Humans, Leg ulcer, Visual analog scale, Wound healing, Heparan sulfate, Article, Case report, Exchange blood transfusion, Excision, Full thickness skin graft, Human, Pain, Priority journal, Recurrent disease, Sickle cell beta thalassemia, Skin transplantation, Ulcer healing, Vacuum assisted closure, Wound dressing, Complication, Sickle cell anemia, Topical drug administration